Teleflex Inc. (TFX) is a recognized global provider of professional medical technologies, primarily targeted towards critical care and surgical applications. The company, with its headquarter located in Wayne, Pennsylvania, has been serving a diverse clientele consisting of hospitals and healthcare providers all around the globe since its inception in 1943. Teleflex Inc. is publicly traded on the New York Stock Exchange (NYSE) under the symbol TFX.
The operational model of Teleflex Inc has been proficiently designed to enhance product development, while keeping patient safety and clinical outcomes at the forefront. They work passionately to deliver a broad spectrum of quality products, from disposable medical devices to surgical instruments. Teleflex's portfolio is highly diversified, featuring product categories like anesthesia, urology, vascular access, respiratory, cardiac care, and surgical care among others. One of their remarkable contributions to the medical industry is the renowned Arrow® branded catheters.
Moreover, Teleflex Inc. continues to pave the way for advancements in the field of interventional access and surgical technology, having successfully acquired NeoTract in 2017, a company that manufactures innovative medical devices particularly for the field of urology.
In addition, the company remains committed to ethical business practices and corporate social responsibility. From taking environmental initiatives to improve resource efficiency, to ensuring the safety of their employees, Teleflex puts great emphasis on sustainable operation and development. The company is also dedicated to providing education and training to healthcare professionals for safe and effective use of their medical technologies.
Teleflex Inc. also has a reputation for financial strength and robust performance, with consistent annual sales growth and an impressive fiscal capacity dedicated towards research and development. Its stocks have proven to be a valuable and reliable investment over time, yielding positive returns. The company attributes its success to the hard work and dedication of its over 14,000 worldwide associates.
Teleflex Inc. continues to invest heavily in research and development, constantly striving to provide improved healthcare solutions. Embarked on a mission to improve the health and quality of people’s lives, Teleflex Inc. has marked its global presence with its innovative and quality medical technology solutions.
Income statement
Balance sheet statement
Cash flow statement
Current assets / Current liabilities
Equity / Debt / Cash
Dividends
Teleflex Inc. (TFX) shares decreased by 1.00% on Tuesday, closing at $124.44, despite an overall negative day for the stock market where the S&P 500 Index and Dow Jones Industrial Average also saw declines. This fall ended a two-day winning streak for Teleflex.
A multinational clinical study published in the American Journal of Infection Control reported that Teleflex's antiseptic-coated central venous catheters were associated with a 70% lower hazard of bloodstream infections in critically ill patients. The study followed 1,750 patients and found significantly lower rates of central line-associated bloodstream infection (CLABSI) with the Arrowg+ard technology. These findings support the use of antiseptic-impregnated catheters in healthcare settings where bloodstream infection rates remain elevated.
Argus has lowered its target price for Teleflex Incorporated (TFX) to $131.00, from a current price of $125.12. Teleflex is described as a Wayne, Pennsylvania-based manufacturer of hospital supplies and medical devices, focusing on bloodstream/vascular and surgical areas.
Teleflex reported strong Q2 2026 results with pro forma adjusted constant currency growth of 4.7% and adjusted EPS of $1.76, exceeding expectations. The company is undergoing a strategic transformation, including the successful divestiture of its OEM business for $1.5 billion, used for debt reduction and share repurchases, and is progressing with other planned divestitures. Despite adjusting down its 2026 revenue outlook due to integration delays in the interventional business, Teleflex increased its adjusted EPS guidance, emphasizing innovation with FDA approval of EZ Plasma and advancements in the FreeZolv clinical trials.
Teleflex Incorporated (NYSE:TFX) has received a "Moderate Buy" consensus rating from Wall Street analysts, with an average 12-month price target of $155.20. The company recently surpassed quarterly earnings expectations, reporting adjusted EPS of $1.76 and revenue of $570.33 million, a 28.9% year-over-year increase. Institutional investors hold a significant portion of the stock, approximately 95.62%, and Teleflex also paid a quarterly dividend of $0.34 per share.
Teleflex Inc. (TFX) shares fell 1.58% to $124.12 on Friday, underperforming the broader market, which saw the S&P 500 Index rise by 0.73% and the Dow Jones Industrial Average increase by 0.49%. The company's stock closed 14.40% below its 52-week high of $145.00, reached on August 6th.